Clinical Trials

Title

A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis. (ARGX-113-2407)

• Short Title ARGX-113-2407
• Category Neurology
• Status Recruiting

Participating Locations

Erlanger

Principal Investigator

Joshua Alpers, MD

Contact

• Name Erlanger Institute for Clinical Research
• Phone 4237783900
• Email [email protected]